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The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor expressed in all skin cell types,
which is critically involved in the pathogenesis of a variety of skin diseases and thus represents a potential
therapeutic target. Recent studies indicate that blocking AHR activation is desirable in some skin conditions,
whereas the opposite, i.e., stimulation of AHR activation, is beneﬁcial in another group of skin disorders. We here
propose a model based on qualitative differences in canonical versus non-canonical AHR signaling to reconcile
these seemingly contradictory observations.
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Sensing and warding off environmental
insults is a crucial function of the skin.
In this context, the aryl hydrocarbon
receptor (AHR) has recently been dis-
covered as an important player in skin
integrity and skin immunity. AHR is
an evolutionarily old, ligand-activated
transcription factor, which is expressed
highly in all skin cell types, and
regulates many genes important for
basic skin functions (Esser et al., 2013;
Furue et al., 2014). On the downside,
AHR signaling was found to be critically
involved in the pathogenesis of several
cutaneous diseases. Therefore, AHR is
increasingly considered an attractive
therapeutic target.
When inactive, AHR is trapped in a
cytosolic multiprotein complex. Ligand
binding dissolves the complex and AHR
can translocate into the nucleus, where it
dimerizes with a partner molecule to
become a functioning transcription factor
at promoters with suitable response ele-
ments. The ﬁrst AHR dimerization partner
discovered was the AHR nuclear translo-
cator (ARNT). AHR:ARNT signaling is
known as canonical signaling, but it has
become clear that activated AHR can
interact in a non-canonical manner with
other signaling cascades, including pro-
inﬂammatory and immune modulatory
molecules, such as the EGFR and down-
stream mitogen–activated protein kinases
(Park and Matsumura, 2006; Fritsche
et al., 2007), NF-κB (Tian et al., 1999;
Vogel et al., 2007), signal transducer
and activator of transcription (STATs;
Kimura et al., 2008; 2009), peroxisome
proliferator–activated receptors (Borland
et al., 2014), and others. This gives AHR
a strong cell-speciﬁc spin, whose regula-
tion is poorly understood. We propose
here that the outcome of AHR activa-
tion markedly differs in healthy versus
inﬂamed skin, which needs to be con-
sidered in AHR-targeting therapies.
Ligands of AHR are abundant in and
on the skin. They include chemicals such
as polycyclic aromatic hydrocarbons
(PAH) and indole derivatives produced
by skin-residing microorganisms (Esser
and Rannug, 2015)––for instance, by
yeasts of the Malassezia strain (Magiatis
et al., 2013; Mexia et al., 2015). In the
absence of exogenous ligands, AHR
signaling in healthy skin is maintained
and regulated via the generation of endo-
genous AHR ligands to assure skin
homeostasis. Speciﬁcally, UV-B rays
are absorbed by free tryptophan in the
cytosol of epidermal cells, which results
in the formation of the photoproduct
6-formylindolo[3,2b]carbazole (FICZ),
a high-afﬁnity ligand for the AHR
(Wei et al., 1999; Fritsche et al., 2007;
Tigges et al., 2014). Interestingly, this
tryptophan photoproduct was recently
identiﬁed as a potent photosensitizer
for UV-A radiation (Park et al., 2015).
Whether and to which extent the photo-
sensitizing property of FICZ inﬂuences
(patho)physiological processes in UV-
exposed skin remains to be elucidated.
Besides FICZ, which is probably ubiqui-
tously distributed in skin cells (Wincent
et al., 2012), AHR activity may be
maintained by kynurenines (Mezrich
et al., 2010), which are generated by
indoleamine-2,3-dioxygenase and trypto-
phan-2,3-dioxygenase during tryptophan
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catabolism (Platten et al., 2012). Notably,
both enzymes are expressed in the
skin, particularly in various skin-residing
immune cells (Santegoets et al., 2008).
In the last decade, several studies have
provided ample evidence that AHR is
involved in the pathogenesis of various
skin diseases and generated excitement
that targeting of AHR may be a novel and
a promising preventive or therapeutic
strategy. The current data, however,
are contradictory. One group of studies
indicates that blocking AHR activity is
suitable to prevent or treat certain skin
diseases (especially skin cancer), whereas
the opposite seems to be true for other skin
disorders (e.g., psoriasis). Accordingly,
activation of AHR in healthy skin by
PAH and UV-B radiation induces cellular
events, which may foster the generation of
reactive metabolites and the accumulation
of damaged macromolecules and thereby
initiate extrinsic aging processes and
carcinogenesis (Esser et al., 2013; Esser
and Rannug, 2015). AHR is a negative
regulator of apopotosis in UV-B-damaged
keratinocytes, indicating its involvement in
initiation of skin cancer (Frauenstein et al.,
2013). In addition, enhanced production
of cytochrome P450 1 enzymes may
lead to the generation of reactive oxygen
species (ROS) and mutagenic PAH meta-
bolites, which may damage proteins and
DNA (Ioannides and Lewis, 2004). AHR
activation is also thought to propagate
tumor formation because it may lead
to an induction of extracellular matrix–
degrading (ECM) matrix metalloproteases
(Murphy et al., 2004; Ono et al., 2013),
as well as pro-inﬂammatory and anti-
apoptotic mediators, such as cyclo-
oxygenase-2 and IL-1β (Sutter et al.,
1991; Fritsche et al., 2007). Importantly,
AHR knockdown reduces photocarcino-
genesis in a mouse model by 50%
(Haarmann-Stemmann et al., 2014).
Thus, inhibition of cutaneous AHR acti-
vity, especially in times of high exposure
to these environmental factors, most
probably protects skin integrity.
This is in striking contrast to the effect
of AHR activation in situations of chronic
inﬂammatory skin diseases including
atopic dermatitis and psoriasis. Topical
treatment of lesional skin with PAH-
containing coal tar is known for a long
time to be beneﬁcial in both skin
diseases. In atopic dermatitis (AD), AHR
activation restores ﬁlaggrin expression
and exerts an anti-inﬂammatory activity
by preventing IL-4- and IL-13-induced
skin inﬂammation. Coal tar–dependent
induction of nuclear factor erythroid
2-related factor 2 (Nrf2) activity and
accompanying anti-oxidant genes neu-
tralizes cytokine-activated STAT-6 and
attenuates downstream pro-inﬂammatory
processes (van den Bogaard et al., 2013).
Topical application of AHR ligands also
dampens skin inﬂammation in psoriasis
(Di Meglio et al., 2014). Stimulation of
human lesional psoriatic skin with FICZ
decreased transcriptional expression of
genes that are expressed at elevated
levels in psoriatic skin, whereas treat-
ment with an AHR inhibitor had
the opposite effect. In addition, in the
imiquimod mouse model of psoriasis
(van der Fits et al., 2009), skin inﬂam-
mation was stronger in AHR-KO mice
compared with their wild-type littermates
and activation of AHR by injection of
FICZ before imiquimod treatment
reduced skin inﬂammation (Di Meglio
et al., 2014). Also, it was suggested that a
ROS-mediated disturbance of AHR sig-
naling contributes to the development of
vitiligo (Schallreuter et al., 2012).
Accordingly, AHR drives skin pigment-
ation (Luecke et al., 2010; Jux et al.,
2011; Nakamura et al., 2013), and, loss
of AHR signaling may partially explain
increased oxidative stress levels in vitiligo
skin, as it can lead to the impaired activa-
tion of the Nrf2 system (Miao et al., 2005;
Tsuji et al., 2012) and thereby reduce
expression of ROS-scavenging enzymes
in vitiligo melanocytes (Jian et al., 2014).
Similar to effective coal tar treatment
in AD and psoriasis, the two most widely
used therapies for vitiligo, Psoralen/
Khellin plus UV-A (PUVA/KUVA) photo-
chemotherapy and exposure to narrow-
band UV-B radiation (Ortonne et al.,
1979; Carlie et al., 2003; Paciﬁco and
Leone, 2011), can activate AHR signaling
(Baumgart et al., 2005; Fritsche et al.,
2007; Vrzal et al., 2013) and may
thereby contribute to repigmentation.
Thus, it appears that alteration of AHR
signaling in the skin may have detri-
mental or beneﬁcial effects depending on
the disease, the participating cells, and
whether or not the immune system is
active concurrently on the systemic or the
local level. In particular, inﬂammatory
situations may change AHR signaling,
possibly shifting it toward non-canonical
pro-inﬂammatory signaling. Accordingly,
AHR inhibition most likely protects
human skin against detrimental conse-
quences of AHR over-activation caused
by environmental toxicants, such as air
pollution and tobacco smoke–associated
PAHs or UV-B radiation, and thereby
reduces the risk of developing skin cancer
and skin aging. In contrast, AHR stimula-
tion appears to be beneﬁcial for the
treatment of AD, psoriasis, and potentially
vitiligo, where the disease has unba-
lanced AHR activity. In order to explain
this Janus-faced role of AHR in the skin,
we here propose that AHR signaling is
qualitatively different in normal healthy
versus chronically inﬂamed skin
(Figure 1).
In healthy skin, AHR signaling driven by
endogenous ligands, such as FICZ, contri-
butes to keratinocyte differentiation, skin
barrier function, and skin pigmentation
(Wei et al., 2000; Wincent et al., 2009;
van den Bogaard et al., 2015). Exposure
to environmental toxicants—which often
are not or only slowly degraded––may
persistently activate the AHR and thereby
disturb this ﬁne-tuned system, leading to
the generation of reactive phase-I metabo-
lites, the generation of ROS, and dysregula-
tion of proteins involved in cell division,
differentiation, migration, and apoptosis.
Depending on the capacity of respective
downstream control or scavenging
mechanisms, this may lead to metabolic
activation of pre-carcinogens, ECM degra-
dation, inﬂammation, and anti-apoptosis
and thus ultimately to skin cancer devel-
opment and extrinsic skin aging. According
to our model (Figure 1), a transient AHR
inhibition is thus clearly desirable, when
environmental pollutants or UV exposure
threatens skin integrity. To this end,
we have developed a novel transiently
acting AHR antagonist E/Z-2-benzyl-
idene-5,6-dimethoxy-3,3-dimethylindan-1-
one (BDDI), which is approved for topical
application to human skin as a cosmetic
ingredient, and shown that BDDI treatment
of deﬁned skin areas blocks AHR-
dependent signaling (Tigges et al., 2014).
The scenario described above, how-
ever, is in contrast to the one present
in chronically inﬂamed skin, such as
AD, psoriasis, and possibly vitiligo.
In chronically inﬂamed skin, AHR
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expression appears to be aberrantly
induced (Kim et al., 2014), probably via
pro-inﬂammatory transcription factors,
such as NF-κB and STAT-3 (Stobbe-
Maicherski et al., 2013; Vogel et al.,
2014). This may lead to silencing or
outcompeting of canonical AHR signaling
and consequently to alterations of the
gene expression proﬁle in the skin. At the
same time, the chronic inﬂammatory state
might enforce non-canonical AHR signal-
ing pathways (e.g., by AHR binding to
NF-κB, c-maf, and STATs), which would
change the production of cytokines or
growth factors in the skin (Tian et al.,
1999; Vogel et al., 2007; Hollingshead
et al., 2008; Kimura et al., 2008, 2009;
Apetoh et al., 2010) and contribute to
disease development and/or persistence.
Administration of potent AHR agonists
may overcome this repressive mechanism
and restore canonical AHR signaling and
thus the balance between canonical and
non-canonical pathways. Thus, for pre-
vention of skin cancer and skin aging, the
preferred strategy should be to prevent or
at least dampen AHR over-activation
resulting from environmental insults. In
contrast, in chronic inﬂammatory skin
diseases, where AHR signaling is unba-
lanced, reconstitution of functional AHR
signaling is desirable, with the goal to
induce AHR/ARNT-regulated genes and
the subsequent promotion of keratinocyte
differentiation and proliferation, skin pig-
mentation, and anti-oxidant defenses.
Given the therapeutic efﬁcacy of PAH-
containing coal tar in AD and psoriasis
and of FICZ-generating photo(chemo)
therapeutic modalities in vitiligo, we
believe that stimulation of AHR with
appropriate ligands can in fact “do the
job”. According to our model, strategies
to reduce oxidative stress, which have
been advocated for the treatment of
vitiligo and AD (Schallreuter et al.,
2013; Sivaranjani et al., 2013), might
also help reconstitute canonical AHR
signaling.
The precise reason why canonical AHR
signaling is compromised under inﬂam-
matory conditions is unclear but may for
instance involve the generation of nitric
oxide (Stadler et al., 1994; Gharavi and
El-Kadi, 2007) or chromatin remodeling
processes at target gene promoters
(Ke et al., 2001). Also, EGFR-signaling-
dependent AHR repression could be
important (Sutter et al., 2009). In addi-
tion, expression levels and relative abun-
dance of the involved molecules might
have a role. Therefore, we also think that
more information on the non-canonical
Xenobiotic-exposed skin
Dominant canonical AHR-signaling
Healthy skin Inflamed skin
Antagonist Agonist
Balanced AHR-signaling Dominant non-canonical AHR-signaling
Leads to:
Reactive intermediates
Anti-apoptosis
Pigmentation
Aging
Cancer
Leads to:
Impaired keratinocyte
Differentiation
Epidermal barrier defects
Cytokine issues
Oxidative stress
Hypopigmentation
Figure 1. Graphic scheme of the hypothesis presented in this paper. In healthy skin (middle), the aryl hydrocarbon receptor (AHR) is constitutively active, and
canonical and non-canonical-mediated signaling processes are tightly balanced. In xenobiotic AHR ligand–exposed skin (left), canonical AHR:aryl hydrocarbon
receptor nuclear translocator (ARNT) signaling may become dominant and lead to a set of adverse effects as indicated in the ﬁgure. In inﬂamed skin (right), high
levels of non-canonical AHR-partner molecules are expressed, unbalancing AHR signaling toward non-canonical inﬂammatory (NCI) AHR:NCI target genes,
resulting in different adverse effects. Balance can be restored by AHR antagonists or agonist, respectively. Possible non-canonical inﬂammatory AHR-partner
molecules, such as NF-κB, have been described in the literature; for details see text. The dendritic cell shown in the epidermal compartment should symbolize the
variety of skin-resident immune cells.
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pathways is needed to fully explore the
potential of AHR as a therapeutic target.
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